Welcome to our dedicated page for Wearable Devices Ltd. SEC filings (Ticker: WLDS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Wearable Devices Ltd. (WLDS) SEC filings page on Stock Titan aggregates the company’s public reports as a foreign private issuer, giving investors structured access to its regulatory disclosures. Wearable Devices files primarily on Form 6-K under the Securities Exchange Act of 1934, and these reports often attach press releases or transaction documents that explain key corporate and financing events.
Recent 6-K filings describe registered direct offerings of ordinary shares and pre-funded warrants, concurrent private placements of ordinary warrants, and an at-the-market sales agreement for ordinary shares. These filings outline terms such as offering structures, use of registration statements on Form F-3, warrant exercise conditions, lock-up provisions and commission arrangements with placement agents or sales agents. Other 6-Ks cover matters like annual and special general meetings, amendments to the company’s compensation policy, and increases in authorized share capital through changes to its articles of association.
For those analyzing WLDS, the filings also reference clinical and technology milestones when they are furnished as exhibits, such as the neurorehabilitation pilot with Soroka University Medical Center and grant support from the Israel Innovation Authority. While detailed financial statements are not included in the excerpts provided here, the 6-K framework allows the company to incorporate press releases and legal opinions by reference into existing registration statements on Form F-3 and Form S-8.
On Stock Titan, users can review these WLDS filings in chronological order and use AI-powered summaries to interpret complex legal and transactional language. The platform highlights essential elements of each report—such as the nature of an offering, key conditions, and referenced exhibits—so readers can more quickly understand how each filing relates to Wearable Devices’ capital structure, governance decisions and product-related disclosures.
Wearable Devices Ltd. (WLDS) prospectus supplement discloses capital structure changes, outstanding equity instruments, and a going-concern uncertainty. The company reports multiple classes of reserved and issuable Ordinary Shares (including options, warrants, RSUs and pre-funded warrants) totaling millions of potential shares that would dilute existing holders if issued. Pro forma adjustments reflect recent financings and a contemplated offering that raise net proceeds and increase pro forma net tangible book value per share from $1.67 to $1.91, and to $2.31 after this offering, with dilution per new investor estimated at $3.69 (61.48%). The filing lists specific reserved amounts (for example, 3,322,000 shares subject to shareholder approval and 564,059 RSUs) and describes distribution mechanics, underwriting limits, and legal/expense items.
Wearable Devices Ltd. entered into a Securities Purchase Agreement with a single institutional investor for a $4 million financing consisting of a registered direct offering and a concurrent private placement. The company is selling 440,000 ordinary shares at $6.00 per share and pre-funded warrants for 230,000 shares at $5.9999 each, with each pre-funded warrant exercisable for one share at an exercise price of $0.0001 and subject to a 9.99% beneficial ownership cap.
In the concurrent private placement, the company will issue ordinary warrants for up to 670,000 shares, exercisable immediately at $6.00 per share and expiring on September 16, 2030. These ordinary warrants and the underlying shares are offered under a private placement exemption, with the company obligated to register the warrant shares on Form F-3 as soon as practicable. A.G.P./Alliance Global Partners is acting as exclusive placement agent, earning a 7.0% placement fee, a 1.0% management fee, and up to $50,000 in expense reimbursement. The company agreed to 60-day restrictions on additional equity issuances and variable rate transactions, subject to specified exceptions.